Novo Nordisk’s subcutaneous weight-loss drug Wegovy will hit Australian shelves this month, two years after it received TGA approval. The once-weekly injectable semaglutide formulation will…
Patients with a BMI of ≥25kg/m2, a waist-to-height ratio of ≥0.5 and any medical complications should be diagnosed with obesity, according to a new clinical…
Semaglutide is associated with non-arteritic anterior ischaemic optic neuropathy among patients with type 2 diabetes and those with overweight or obesity, according to a US…
Type 2 diabetes drug tirzepatide has been shown to be effective in treating moderate to severe sleep apnoea in a worldwide clinical trial. US researchers…
When Dr Manfred Penzhorn prescribes antidepressants, he tells patients they are “almost certainly” about to put on weight. “Very few psychiatric medications don’t cause some…
New safety warnings about the risk of ileus have been added to all GLP-1 receptor agonists following a TGA investigation into local reports of the…
Patients taking GLP-1 receptor agonists within four weeks of anaesthesia for non-endoscopic procedures should be considered non-fasted, according to new guidance. Doctors are also advised…
Bariatric surgery significantly decreases the conversion from prediabetes to type 2 diabetes, according to a study presented at the annual meeting of the American Society…
People trying to control their blood glucose levels might do best to work out in the evening, a study suggests. Exercise performed between 6pm and…
Former deputy chief medical officer Dr Nick Coatsworth says the Federal Government’s looming ban on compounded semaglutide fails to recognise the life-changing effect of the…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
